1 janv. 2004 - FDA approves first "anti-angiogenic" drug, bevacizumab

Description:

Bavacizumab is the first of a new generation of targeted drugs that attacked cancer by blocking blood flow to the tumors.

Ajouté au bande de temps:

16 nov. 2018

0

0

254

Cancer Dates

Date: